Home | About | RSS Feed | Contact and Publicity Guidelines | Comment Policy the Law, the Universe, and Everything 

advertise-here4


Slip Opinions


First they came for the birthday card . . . (fp)

Let the jailbreaking begin! (kw)

For the Niall denial files. (fp)

Professors as processors. (fp)

Great Moderation hits Great Mortification. (fp)

Understanding the Shirley Sherrod story. (fp)

Credit score cruelty. (fp)

Slowing Interior's revolving door. (fp)

Great risk shift: Americans more insecure; BC/BS enjoying a surplus. (fp)

Leamer: Economic theory is fiction; econometrics is journalism. (fp)

Our Podcast

Subscribe to Law Talk

law-rev-contents2.jpg


  • Posts by Author

  • Categories

  • Archives


  • Recent Comments


    • Harris Telemacher on Starbucks' Secret Menu

    • Patrick S. O'Donnell on Three Defenses of Markets

    • Nate Oman on Three Defenses of Markets

    • Patrick S. O'Donnell on Three Defenses of Markets

    • Michael S. Langston on Three Defenses of Markets

    • Nate Oman on Three Defenses of Markets

    • Patrick S. O'Donnell on Three Defenses of Markets

    • Nate Oman on Three Defenses of Markets

    • Nate Oman on Three Defenses of Markets

    • Frank Pasquale on Three Defenses of Markets

    • A.J. Sutter on Three Defenses of Markets

    • Jeff Lipshaw on Three Defenses of Markets

    • Jeff Lipshaw on Three Defenses of Markets

    • Marc DeGirolami on Three Defenses of Markets

    • Jeff Lipshaw on Three Defenses of Markets
  •  

    Site Meter

    About the Blog

    Concurring Opinions is a multiple authored, general interest legal blog.

    (Image: Wikicommons)

Alternative Revenue Stream for Private Practice Physicians – Research Investigator

posted by Kathleen Boozang

Clinical research is the only way [for a physician in the managed care era] to make a boat payment, quips David Stark, M.D.

 

With increasing frequency, pharmaceutical and medical device companies are turning to physicians in private practice, rather than academic medical centers, to serve as investigators overseeing the 60,000-odd clinical trials each year, between 80 and 90% of which are funded by industry as opposed to, say, NIH. Academic medical centers are losing the “business,” having fallen from 63% to 26% as the site for clinical research between 1994 and 2004. While it might be argued that trials in the private practice setting produce superior results because they occur under circumstances that more closely resemble how the drug or device will actually be used if approved by the FDA, there are significant risks attendant to this phenomenon that have received too little attention.

The ultimate question is whether physicians can compartmentalize the competing incentives that exist in advising patients about whether to pursue conventional therapy or participate in a clinical trial. This is especially true if the physician is being handsomely compensated for each patient she recruits into a trial, and is exacerbated when the physician also has other financial relationships with the trial sponsor (the drug or device company) for, say, speaking and consulting gigs.  The recruitment process for clinical trials is the longest and most costly part of the process – prospective participants have to undergo testing to see if they qualify for the study, and federal law requires that they receive significant amounts of information and have ample opportunity to have their questions answered pre-enrollment. A per capita payment contingent upon successful enrollment of the patient will tempt a physician to fudge on this process and enroll unqualified subjects. This not only may put them at risk because they are too sick, but also skew the research results because they’re not sick enough. Bonuses for meeting enrollment goals only make it worse.

Without impugning physician integrity, how realistic it is for physicians to serve in the dual capacity of treating physician and researcher? Studies have repeatedly confirmed “therapeutic misconception” whereby study participants believe, no matter how clearly told to the contrary, that they are “patients” receiving treatment, rather than “subjects” of research who may be receiving a placebo or an experimental drug. This phenomenon is certainly exacerbated when the patient’s treating physician is doubling as the investigator of the clinical trial. Most patients continue to believe that their own personal physician would be driven solely by their best interests.  Ironically, research shows that some people have more faith in an experimental intervention when they learn that the investigator has a “piece of the action.”

Obviously, significant policy and legal questions arise from this practice, and a more holistic approach to the question of the best way to encourage clinical trials while safeguarding the interests of trial subjects is beyond what I can attempt here. But one possible approach could be drawn from informed consent law – whether statutory or common law, which should require physician disclosure of conflicts of interest to patients. Imagine the beginning of a conversation between doctor and patient/potential research subject:

Doctor: “Just so you know, if you agree to participate in this clinical trial, I get paid $1000 by the manufacturer of the product being tested, but if you don’t, and you just want regular treatment, I’ll only get paid $60 by your insurance company. But, in fairness, that’s because a clinical trial is a lot more work for me….”

But to be honest, I don’t really believe in this solution either. Most recipients of this information either don’t understand it, or have no idea what to do with it, or both. Some fear that too much confusion information might kill trials altogether, which would be a terrible outcome. And there are certainly reasons to fear that such trials are becoming harder to run, to the point where they are not worth the money.

Ultimately, I guess, I want to control how physicians get paid to serve as investigators – the Goldilocks Solution – not too much, and not too little. I want them to be paid just right, so that they are willing to conduct clinical trials, but aren’t tempted to act other than in the patient’s best interest. Of course, what is just right and how to enforce it poses its own problems.

Seton Hall Law School, the author’s employer, is the recipient of grants, donations and endowments from the pharmaceutical industry. No part of the author’s compensation is funded by these gifts.


 September 1, 2009 at 3:24 pm   Posted in: Uncategorized   Print This Post Print This Post

Responses (2)

  1. Alternative Revenue Stream for Private Practice Physicians – Research Investigator : HEALTH REFORM WATCH - September 1, 2009 at 8:37 pm

    [...] x-posted at Concurring Opinions [...]

  2. jeri harris - November 25, 2009 at 5:37 pm

    i really hope someone out there is reading this… i could use some advice. my husband was diagnosed with esophageal cancer in jan. 08. we went to harvard doc, great rep, and he suggested a clinical trial, sarah cannon, gi 91 as an option. first, we had to have an mri, pet and cat scan to be sure that it hadn’t spread as the trial was for stage 3 only. the goal was to be able to have the “curative” surgery after chemo radiation. got test results back after much gut wrenching waiting, and we got the call. the doc’s nurse said that “dr. rubin was not calling the spots on the liver cancer, they only slightly lit up on the pet scan. we were a little concerned about the spots, but hey, they are the docs, we’ll take it. as my husband was only 47 years old, we were told that he would be a great candidate for the study as he was quite young for the cancer. we jumped right in, chemo radiation began, and of course, he got sicker and sicker. but, we were optimistic about the end results. we had our visit with the surgeon, well known surgeon at moffit hospital in tampa fl, his expertise was esophageal cancer, and he told us that he would have to have a pet scan for the liver “cysts” to make sure they weren’t cancer. so of course, we were scared to death, had the pet scan, and anxiously awaited the results. we went in for the pre surgery visit, i had to ASK how the test results came back, and he said oh ya, that’s right, he pulled up some scan that now looking back was probably a cat scan not a pet, and said oh, it’s fine. never explained anything. he had the horrific surgery, lived with horrific aftermath, in and out of hospitals for 4 months before the next check ups, and of course, the post surgery pet came back with metastized cancer in the liver, which would have disqualified him from the beginning, which we came to find out. the dr. we chose to see after getting the dismal news told us it was cancer from the beginning, stage 4, not 3. needless to say, he died of liver cancer 1 year after the surgery. i now have an attorney, but i really believe that he was put into the study for financial gain, along with the surgery. these docs should lose their licenses, as every doc that has seen the original scans said it was unequivocally cancer in the liver at the start, and surgery should never have been done. i feel like a victim of the clinical study laxness for not requiring that they see the tests done for all applicants of clinical studies, and certainly a victim of the docs who knew better, no other reason than money makes any sense. can anyone out there give me some advice, how to make some noise with this, i know we are not the only ones going thru this and this needs to stop. the doc works for florida cancer specialists, who now go by the name “florida cancer specialists and research organization. all that says to me is more people are going to be put thru the research mill for these docs and clinical research people to make lots of money as we now are trying to get over the nightmare of watching my husband struggle to survive after a surgery he should have NEVER had by all standard of care guidelines. HELP!!!! JERI HARRIS

Leave a Reply

Spam protection by WP Captcha-Free


  • « Previous post
  • Next post »

Authors

Daniel J. Solove
Kaimipono Wenger
Dave Hoffman
Nate Oman
Frank Pasquale
Deven Desai
Danielle Citron
Lawrence Cunningham
Sarah Waldeck
Jaya Ramji-Nogales
Solangel Maldonado
Gerard Magliocca

Guests

Thomas Crocker
Kristin Johnson
Tuan Samahon
Corey Yung




Need A Solicitor?
Find the right solicitor to advise you on all your litigation law, employment law, divorce law and family law related matters. Use the award winning legal search and matching service from TakeLegalAdvice.com









Previous Guests

Michael Abramowicz
Michelle Adams
Robert Ahdieh
Michelle Anderson
Laura Appleman
Ann Bartow
Adam Benforado
Gaia Bernstein
Francesca Bignami
Jeremy Blumenthal
Kathleen Boozang
Bruce Boyden
Donald Braman
Al Brophy
Neil H. Buchanan
Bill Burke-White
Scott Burris
Paul Butler
Naomi Cahn
Anupam Chander
Miriam Cherry
Jack Chin
Jennifer Collins
Thomas Crocker
Allison Danner
Brannon Denning
Deven Desai
Mike Dimino
Mark Edwards
David Fagundes
Lisa Fairfax
Christine Haight Farley
Kim Ferzan
Dan Filler
Michael Froomkin
Amanda Frost
Timothy Glynn
Rachel Godsil
Eric Goldman
David Gray
Craig Green
Tristin Green
Michelle Harner
Jeffrey Harrison
Erica Hashimoto
Carissa Hessick
Laura Heymann
Robert Hillman
Christine Hurt
Darian Ibrahim
Sherrilyn Ifill
John Ip
Kevin Johnson
Kristin Johnson
Dan Kahan
Jeffrey Kahn
Brian Kalt
Sam Kamin
Michael Kang
Chimène Keitner
Orin Kerr
Nancy Kim
Heidi Kitrosser
Adam Kolber
Russell Korobkin
Alex Kreit
Anita S. Krishnakumar
Susan Kuo
Greg Lastowka
Sarah Lawsky
Youngjae Lee
Erik Lillquist
Jeff Lipshaw
Jonathan Lipson
Jacqueline Lipton
Joseph Liu
Michael Madison
Solangel Maldonado
Jason Mazzone
Linda McClain
William McGeveran
Salil Mehra
Carrie Menkel-Meadow
Max Minzner
Viva Moffat
Scott Moss
Eric Muller
Jaya Ramji-Nogales
Helen Norton
Elizabeth Nowicki
Paul Ohm
Angela Onwuachi-Willing
Michael O'Shea
David Opderback
Kristen Osenga
Rafael Pardo
Marcy Peek
Eduardo Peñalver
Robert Percival
Marc Poirier
David Post
Shruti Rana
Geoffrey Rapp
Neil Richards
Lori Ringhand
Alice Ristroph
Susan Scafidi
Paul Secunda
Jonathan Siegel
Jessica Silbey
Peter Smith
Judd Sneirson
Adam Steinman
Charles Sullivan
Rick Swedloff
Steph Tai
Andrew Taslitz
Robert Tsai
Jenia Turner
Steve Vladeck
Spencer Weber Waller
Howard Wasserman
Melissa Waters
Frank Wu
Alfred Yen
Corey Yung
David Zaring
Timothy Zick
Michael Zimmer
Jonathan Zittrain

Ownership

Concurring Opinions is a
general-interest legal blog
operated by Concurring
Opinions LLC, a Pennsylvania
Limited Liability Corporation.

Blogroll

Above the Law
ACS Blog
Althouse
Balkinization
Becker-Posner Blog
BlackProf
BoingBoing
Chicago Law Faculty Blog
Conglomerate
CrimLaw
Crime & Federalism
CrimProf Blog
Crooked Timber
Derechoalderecho
Discourse.net
Dorf on Law
Election Law
Emergent Chaos
The Faculty Lounge
Feminist Law Profs
43(B)log
Freakonomics Blog
Freedom to Tinker
Google Blogoscoped
How Appealing
Ideoblog
Info/Law
Instapundit.com
Juris Novus
Jurisdynamics
Just Books
Law and Humanities Blog
Law and Letters
Law Librarian Blog
Legal Profession Blog
Legal Theory Blog
Legal Times Blog
Leiter Reports
Brian Leiter's Law School Reports
Lessig Blog
Madisonian Theory
Media Law Blog
Mirror of Justice
The Moderate Voice
National Security Advisors
Opinio Juris
Point of Law
PrawfsBlawg
ProfessorBainbridge.com
Property Prof Blog
Red Tape Chronicles
The Right Coast
Schneier on Security
SCOTUSBlog
Security Dilemmas
Sentencing Law and Policy
Simple Justice
Sivacracy.net
The Situationist
Susan Crawford
TalkLeft
Talking Points Memo
TaxProf Blog
Tech & Marketing Law
Truth on the Market
Volokh Conspiracy
WorkPlace Prof Blog
WSJ Law Blog
Wonkette
The Yin Blog


© Concurring Opinions

Powered by WordPress